1 |
Wroblewski, L. E., Piazuelo, M. B., Chaturvedi, R., Schumacher, M., Aihara, E., Feng, R. Noto, J. M., Delgado, A., Israel, D. A., Zavros, Y., Montrose, M. H., Shroyer N., Wilson, K. T. and Peek, R. M. Jr. 2015. Helicobacter pylori targets cancer-associated apical-junctional constituents in gastroids and gastric epithelial cells. Gut 64, 720-730.
DOI
|
2 |
Zhang, X. Y., Chan, W. Y., Whitney, B. M., Fan, D. M., Chow, J. H., Liu, Y., Ng, E. K. and Chung, S. C. 2002. Changes of interleukin expression correlate with Helicobacter pylori infection and lymph node metastases in gastric carcinoma. Diagn. Mol. Pathol. 11, 135-139.
DOI
|
3 |
Kang, D. W., Park, M. H., Lee, Y. J., Kim, H. S., Kwon, T. K., Park, W. S and Min, D. S. 2008. Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/Ras/ERK/NFκB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells. J. Biol. Chem. 283, 4094-4104.
DOI
|
4 |
Kang, D. W., Noh, Y. N., Hwang, W. C., Choi, K. Y. and Min, D. S. 2016. Rebamipide attenuates Helicobacter pylori CagA-induced self-renewal capacity via modulation of bcatenin signaling axis in gastric cancer-initiating cells. Biochem. Pharmacol. 113, 36-44.
DOI
|
5 |
Lamb, A., Yang, X. D., Tsang, Y. H., Li, J. D., Higashi, H., Hatakeyama, M., Peek, R. M., Blanke, S. R. and Chen, L. F. 2009. Helicobacter pylori CagA activates NFκB by targeting TAK1 for TRAF6-mediated Lys 63 ubiquitination. EMBO Rep. 10, 1242-1249.
DOI
|
6 |
Hanahan, D. and Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70.
DOI
|
7 |
Sier, C. F., Kubben, F. J., Ganesh, S., Heerding, M. M., Griffioen, G., Hanemaaijer, R. van Krieken, J. H., Lamers, C. B. and Verspaget, H. W. 1996. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to overall survival of patients with gastric carcinomas. Br. J. Cancer 74, 413-417.
DOI
|
8 |
Mori, N., Sato, H., Hayashibara, T., Senba, M., Geleziunas, R., Wada, A., Hirayama, T. and Yamamoto, N. 2003. Helicobacter pylori induces matrix metalloproteinase-9 through activation of NFκB. Gastroenterology 124, 983-992.
DOI
|
9 |
Murakami, K., Okajima, K., Uchiba, M., Harada, N., Johno, M. Okabe, H. and Takarsuki, K. 1997. Rebamipide attenuates indomethacin-induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats. Dig. Dis. Sci. 42, 319-325
DOI
|
10 |
Ohnishi, N., Yuasa, H., Tanaka, S., Sawa, H., Miura, M., Matsui, A., Iwabuchi, K., Suzuki, M., Yamada, G., Azuma, T. and Hatakeyama, M. 2008. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc. Natl. Acad. Sci. USA 105, 1003-1008.
DOI
|
11 |
Styczynski, J. and Drewa, T. 2007. Leukemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting. Acta. Biochim. Pol. 54, 717-726.
|
12 |
Su, W., Chen, Q. and Frohman, M. A. 2009. Targeting phospholipase D with small molecule inhibitors as a potential therapeutic approach for cancer metastasis. Future Oncol. 5, 1477-1486.
DOI
|
13 |
Tanigawa, T., Pai, R., Arakawa, T. and Tarnawski, A. S. 2007. Rebamipide inhibits gastric cancer cell growth. Dig. Di.s Sci. 52, 240-247.
DOI
|
14 |
Yamasaki, K., Kanbe, T., Chijiwa, T., Ishiyama, H. and Morita, S. 1987. Gastric mucosal protection by OPC-12759, a novel antiulcer compound in rats. Eur. J. Pharmacol. 142, 23-29.
DOI
|
15 |
Tarnawski, A., Pai, R., Chiou, S. K., Chai, J. and Chu, E. C. 2005. Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem. Biophys. Res. Commun. 334, 207-212.
DOI
|
16 |
Tsukamoto, H., Mizoshita, T., Katano, T., Hayashi, N., Ozeki, K., Ebi, M. Shimura, T., Mori, Y., Tanida, S., Kataoka H., Tsukamoto, T., Tatematsu, M. and Joh, T. 2015. Preventive effect of rebamipide on N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Exp. Toxicol. Pathol. 67, 271-277.
DOI
|
17 |
Yamane, T., Nakatani, H., Matsumoto, H., Iwata, Y., Kikuoka, N. and Takahashi, T. 1998. Inhibitory effects of rebamipide on ENNG-induced duodenal carcinogenesis in mice: a possible strategy for chemoprevention of gastrointestinal cancers. Dig. Dis. Sci. 43, 11S-207S.
|
18 |
Yasuda, Y., Chiba, H., Satomi, T., Matsuo, A., Kaneko, T. and Chikazu, D. 2012. Preventive effect of rebamipide gargle on chemoradiotherpy-induced oral mucositis in patients with oral cancer: a pilot study. J. Oral Maxillofac. Res. 2, 1-8.
|
19 |
Yin, Y., Grabowska, A. M., Clarke, P. A., Whelband, E., Robinson, K., Argent, R. H., Tobias, A., Kumari, R., Atherton, J. C. and Watson, S. A. 2010. Helicobacter pylori potentiates epithelial:mesenchymal transition in gastric cancer: links to soluble HB-EGF, gastrin and matrix metalloproteinase-7. Gut 59, 1037-1045.
DOI
|
20 |
Yoshikawa, T., Naito, Y. and Kondo, M. 1993. Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung 43, 363-366.
|
21 |
Charafe-Jauffret, E., Monville, F., Ginestier, C., Dontu, G., Birnbaum, D. and Wicha, M. S. 2008. Cancer stem cells in breast: current opinion and future challenges. Pathobiology 75, 75-84.
DOI
|
22 |
Aihara, M., Azuma, A., Takizawa, H., Tsuchimoto, D., Funakoshi, Y., Shindo, Y. Ohmoto, Y., Imagawa, K., Kikuchi, M., Mukaida, N. and Matsushima, K. 1998. Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. Dig. Dis. Sci. 43, 174S-180S.
|
23 |
Arakawa, T., Kobayashi, K., Yoshikawa, T. and Tarnawski, A. 1998. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig. Dis. Sci. 43, S5-13.
|
24 |
Bagnoli, F., Buti, L., Tompkins, L., Covacci, A. and Amieva, M. R. 2005. Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes in MDCK cells. Proc. Natl. Acad. Sci. USA 102, 16339-16344.
DOI
|
25 |
Baud, J., Varon, C., Chabas, S., Chambonnier, L., Darfeuille, F. and Staedel, C. Helicobacter pylori initiates a mesenchymal transition through ZEB1 in gastric epithelial cells. PLoS One 8, e60315.
DOI
|
26 |
Bessède, E., Staedel, C., Acuña Amador, L. A., Nguyen, P. H., Chambonnier, L., Hatakeyama, M., Belleannée G., Mégraud, F. and Varon, C. 2014. Helicobacter pylori generates cells with cancer stem cell properties via epithelial–mesenchymal transition-like changes. Oncogene 33, 4123-4131.
DOI
|
27 |
Kang, D. W., Min, G., Park, D. Y., Hong, K. W. and Min, D. S. 2010. Rebamipide-induced downregulation of phospholipase D inhibits inflammation and proliferation in gastric cancer cells. Exp. Mol. Med. 42, 555-564.
DOI
|
28 |
Ishihara, K., Komuro, Y., Nishiyama, N., Yamasaki, K. and Hotta, K. 1992. Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittelforschung 2, 1462-1466.
|
29 |
Kang, D. W., Hwang, W. C., Park, M. H., Ko, G. H., Ha, W. S., Kim, K. S., Lee, Y. C., Choi, K. Y. and Min, D. S. 2013. Rebamipide abolishes Helicobacter pylori CagA-induced phospholipase D1 expression via inhibition of NFkappaB and suppresses invasion of gastric cancer cells. Oncogene 32, 3531-3542.
DOI
|